Drug news
Brilinta/Brilique(AstraZeneca) study in Peripheral Vascular Disease
Astra Zeneca will commence a new study called EUCLID of Brilinta/Brilique(ticagrelor) to compare twice daily dosing of Brilinta/Brilique with once dosing daily of now generic Plavix (clopidogrel) in 11 500 patients with Peripheral Vascular Disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.